Inventor · disambiguated record
Michael Meehl
Also filed as: MEEHL MICHAEL · MEEHL MICHAEL A
5 granted patents·5 pending applications·16 citations·filing 2010–2021
69Inventor score
Top patents by PatentIndex Score
10 records- 0190US8715963B2Method for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in Pichia pastorisSETHURAMAN NATARAJAN·Filed 2011·Granted May 6, 2014·16 cites·18 claims
- 0271US12441792B2Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereofMERCK SHARP & DOHME·Filed 2021·Granted Oct 14, 2025·0 cites·13 claims
- 0371US12435133B2Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereofMERCK SHARP & DOHME LLC·Filed 2021·Granted Oct 7, 2025·0 cites·15 claims
- 0469US11111297B2Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereofMERCK SHARP & DOHME·Filed 2018·Granted Sep 7, 2021·0 cites·21 claims
- 0555US2014227290A1Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastorisMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 0650US9707276B2O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analoguesMERCK SHARP & DOHME·Filed 2013·Granted Jul 18, 2017·0 cites·16 claims
- 0744US2016289290A1N-glycosylated insulin analoguesMERCK SHARP & DOHME·Filed 2016·Application pending·0 cites
- 0838US2013011875A1Methods for the production of recombinant proteins with improved secretion efficienciesMERCK SHARP & DOHME·Filed 2010·Application pending·0 cites
- 0937US2014235537A1N-glycosylated insulin analoguesMEEHL MICHAEL·Filed 2012·Application pending·0 cites
- 1027US2012213728A1Granulocyte-colony stimulating factor produced in glycoengineered pichia pastorisMEEHL MICHAEL·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Meehl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →